Leptin
Phase 2Small molecule
Leptin is one of 140 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 2.
4
Indications
11
Total Trials
0
Active Trials
139
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
249 competitors in Type 1 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskPhase 3
Symlin
AstraZenecaPhase 3
Suglat
AstellasPhase 3
Galvus
NovartisPhase 3
Tecfidera
BiogenPhase 3
Inpefa
LLexicon Pharmaceuticals
Phase 3
Simulect
NovartisPhase 3
Zinbryta
RochePhase 3
Zegalogue
Zealand PharmaPhase 3
LY2605541
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lipodystrophy2 trials
Homeostasis1 trial
Leptin in Human Energy and Neuroendocrine Homeostasis
Terminated·—·N/A·NCT00265980·22 enrolled
Humans1 trial
In Vivo Leptin Signaling in Humans After Acute Leptin Administration
Completed·—·Phase 1·NCT01275053·12 enrolled
5 more indications
Gastric1 trial
Trial of Leptin Administration After Roux-en-Y Gastric Bypass
Completed·—·Phase 1/2·NCT00710814·31 enrolled
Body Weight1 trial
Leptin in the Maintenance of Reduced Body Weight
Completed·—·Phase 2·NCT01155180·24 enrolled
Metabolic Syndrome1 trial
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
Completed·—·Phase 2·NCT00362440·9 enrolled
Obese1 trial
Low-Dose Leptin and the Formerly-Obese
Unknown status·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00073242·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Leptin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details